Key Drivers
- Strong Balance Sheet
- Weak Cash Conversion
- Full Valuation
AIAI Summary
REX should be viewed less as a broad growth theme and more as a cyclical operator with a fortress balance sheet but weakening cash conversion, so the real investment test is whether earnings can consistently turn into free cash flow before the stock's ~19x valuation and weak near-term tape catch up.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Balance Sheet
- •Weak Cash Conversion
- •Full Valuation
REX has strong liquidity, low leverage, and solid profitability, but its recent weak free cash flow, meaningful capex, and fairly full valuation temper the investment case.
Price Behavior
Key Price Behavior Insights:
- •Support base
- •Overhead resistance
- •Rebound unconfirmed
REX is stabilizing after a sharp mid-June selloff, but last month's trend still points lower until it can reclaim and hold above the $45.50-$46.30 resistance zone.
Rebounded from the
Sentiment & News
Key News Insights:
- •Insider Sale
- •Record Earnings
- •Preclinical Progress
REX drew attention for a $663K insider sale following record earnings and strong share gains, while Recludix Pharma advanced early-stage REX-8756 data in allergic and atopic inflammation research.
The news is modestly positive for sentiment, as strong operational results and pipeline updates support interest despite the insider sale
Similar Companies in Basic Materials
Other companies in the same sector with AI ratings